CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
Type
Private
HQ
King of Prussia, US
Founded
1901
Size (employees)
4,738 (est)+3%
CSL Behring was founded in 1901 and is headquartered in King of Prussia, US
Report incorrect company information

Key People/Management at CSL Behring

David Lamont

David Lamont

Chief Financial Officer
Gordon Naylor

Gordon Naylor

President, Seqirus
Val Romberg

Val Romberg

Executive Vice President Manufacturing Operations and Planning
Andrew Cuthbertson

Andrew Cuthbertson

Chief Scientific Officer and R&D Director
Bill Campbell

Bill Campbell

Executive Vice President and Chief Commercial Officer
Karen Etchberger

Karen Etchberger

Executive Vice President Quality and Business Services
Show more

CSL Behring Office Locations

CSL Behring has an office in King of Prussia
King of Prussia, US (HQ)
1020 1st Ave
Show all (1)
Report incorrect company information

CSL Behring Financials and Metrics

Summary Metrics

Founding Date

1901
Report incorrect company information

CSL Behring News and Updates

CSL Behring to buy VC-backed Calimmune

CSL Behring has agreed to acquire Calimmune Inc, a gene therapy company, for an upfront payment of $91 million. Calimmune's backers included Alexandria Venture Investments, RA Capital Healthcare Fund LP and Translational Accelerator LLC.
Report incorrect company information